Ai Technology Group and AVM Biotechnology Provide Merger and Operational Update

Core Viewpoint - The proposed merger between Ai Technology Group Inc. and AVM Biotechnology Inc. is progressing, with funding timelines being extended to facilitate corporate growth and financial audits in 2026 [2] Group 1: Merger and Funding - The Company is funding the proposed merger with AVM on an exclusive basis and is extending funding dates to accommodate the merger and financial audit timelines [2] - The planned merger is expected to enhance the corporate growth of the combined entities [2] Group 2: Clinical Trials and Drug Development - AVM has resumed its FDA Phase 2 Clinical Trial for relapsed and refractory Non-Hodgkins Lymphoma, known as the OPAL Trial, for its drug AVM0703, with plans to enroll an additional 7-10 patients [3] - AVM0703 has been administered in cycles of 3-4 weeks for up to 9 repeat infusions without cumulative safety concerns, with promising survival data accumulating from 30 subjects over almost four years [3] - AVM also runs an FDA Expanded Access Program for various solid tumors and blood cancers, with over 19 repeat infusions administered and follow-up extending beyond 5 years [4] Group 3: Funding and Grants - More than 92 patients have received over 297 total infusions of AVM0703 without safety concerns, yielding exciting outcomes [5] - AVM has secured an additional US$2 million NCI SBIR grant, bringing total government grant funding to US$6.4 million [5]